Takeda Pharmaceutical Company Limited

Other

Cornell University

Tri-institutional Therapeutics Discovery Institute

Daido Tokushuko Kabushiki Kaisha

Patcore, Inc.

Kenjiro Sato

Gang Herbert Lin

Carl F Nathan

Toshihiro Imaeda

Hiroshi Nara

Tzu-Tshin Wong

Rei Okamoto

Michael Andrew Foley

Kazuyoshi Aso

Ryoma Hara

Wenhu Zhan

Trevor Morgan

Jun Terauchi

Takafumi Yukawa

Hideyuki Oki

Akinori Toita

Laura Kirkman

Masanori Kawasaki

John D Ginn

Koji Watanabe

Hiroki Sakamoto

Tatsuki Koike

Takeshi Ueda

Junya Shirai

Takaharu Hirayama

Zenichi Ikeda

Shuji Kitamura

Fumiaki Kikuchi

Hideki Hirose

Akira Kaieda

Minoru Ikoma

Sachie Morimoto

Hiromi Fukuda

Ryozo Echigo

Koichiro Kinto

Takaaki Noda

Kazue Suzuki

Kenta Tamaki

Toru Tanoue

Yuichi Horita

Haruhiko Kuno

Tsutomu Morita

Hiromasa Ishihara

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I′): where the substituents R, R, R, R, R, R, R', R″, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R', R″, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Macrocyclic compounds as proteasome inhibitors

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R, R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, R, R, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Peptidomimetic proteasome inhibitors

An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information. According to an embodiment, this document creation assistance server for assisting with the creation of a document comprises: a final product identification part for accepting identification information for identifying a final product generated by synthesizing a plurality of chemical compounds; a chemical equation acquisition part for referring to electronic experiment note data which provides an electronic record of the details of an experiment relating to the synthesis of the chemical compounds, and acquiring a chemical equation for generating the final product associated with the accepted identification information; and a document generation part for generating a document including the acquired chemical equation.

Document creation assistance server and document creation assistance method

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, RR, R&#x2032;, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues. 

The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

Heterocyclic compound

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR(Ris a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, Ris a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X' is S, O, SO, or CH), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl} 5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof. 

Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR(Ris a hydrogen atom or an optionally substituted hydrocarbon group),is a single bond or a double bond, Ris a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X' is S, O, SO, or CH), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof. 

Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors

A pillow for enabling a patient with whiplash syndrome to sleep peacefully including a deformable pillow body having an upper surface cloth and a lower surface cloth with an edge cloth as a boundary, a depression part including a bottom surface at a position depressed from the upper surface cloth to the lower surface cloth of the pillow body and a grooved part extending from the depression part to the edge cloth of the pillow body and being formed by joining the upper surface cloth to the lower surface cloth.

Pillow

The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. wherein each symbol is as defined in the specification.

Heterocyclic amide compound and use thereof

The vacuum carburizing apparatus introduces a carburizing gas into a carburizing chamber to subject the treatment material to vacuum carburizing. The vacuum carburizing apparatus comprises a carburizing chamber that houses a treatment material therein, a vacuum pump that exhausts gas from the carburizing chamber inside to obtain vacuum, a carburizing gas supply unit that supplies carburizing gas into the carburizing chamber in pulse mode, a reflux pipe which connects an intake side of the vacuum pump and an exhaust side of the vacuum pump, an opening and closing valve which is provided on the way of the reflux pipe, and a control unit which opens the opening and closing valve when a supply of the carburizing gas into the carburizing chamber is started, wherein the control unit closes the opening and closing valve when the supply ends.

Vacuum carburizing apparatus

A radiant tube to be heated by high-temperature gases supplied from its one end. The tube supplys a heat radiation by being thus heated. The gases used for the heating are discharged from the other end of the tube. Inside the tube a heat exchanger is provided in the proximity of the gas outlet of the tube so as to recover thermal energy from the used gases before they come out from the outlet.

Recuperative radiant tube

Growing community of inventors

Kanagawa, Japan

Kenjiro Sato